The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components
暂无分享,去创建一个
[1] M. Maiuri,et al. Autophagy Alteration in ApoA-I Related Systemic Amyloidosis , 2022, International journal of molecular sciences.
[2] D. Middleton,et al. Raman spectroscopy with 2D perturbation correlation moving windows for the characterisation of heparin-amyloid interactions. , 2020, Analytical chemistry.
[3] S. Ekström,et al. Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux , 2020, bioRxiv.
[4] L. Eliasson,et al. Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion. , 2019, Biochimica et biophysica acta. Molecular basis of disease.
[5] J. Lagerstedt,et al. High‐efficient bacterial production of human ApoA‐I amyloidogenic variants , 2018, Protein science : a publication of the Protein Society.
[6] J. Straub,et al. Molecular Insights into Human Hereditary Apolipoprotein A-I Amyloidosis Caused by the Glu34Lys Mutation. , 2018, Biochemistry.
[7] N. Goto,et al. Two novel APOA1 gene mutations in a Japanese renal transplant recipient with recurrent apolipoprotein A‐I related amyloidosis , 2018, Nephrology.
[8] R. Piccoli,et al. Cell milieu significantly affects the fate of AApoAI amyloidogenic variants: predestination or serendipity? , 2018, Biochimica et biophysica acta. General subjects.
[9] D. Monti,et al. Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[10] Joan Domingo-Espín,et al. Synchrotron radiation circular dichroism spectroscopy reveals structural divergences in HDL-bound apoA-I variants , 2017, Scientific Reports.
[11] Shobini Jayaraman,et al. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis , 2017, Proceedings of the National Academy of Sciences.
[12] C. Dobson,et al. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. , 2017, Annual review of biochemistry.
[13] D. Middleton,et al. Heparin and Methionine Oxidation Promote the Formation of Apolipoprotein A-I Amyloid Comprising α-Helical and β-Sheet Structures. , 2017, Biochemistry.
[14] T. Rudd,et al. High-throughput SRCD using multi-well plates and its applications , 2016, Scientific Reports.
[15] H. Saito,et al. Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes , 2016, Scientific Reports.
[16] J. Nan,et al. Heparin interactions with apoA1 and SAA in inflammation-associated HDL. , 2016, Biochemical and biophysical research communications.
[17] S. Cushman,et al. Dual Actions of Apolipoprotein A-I on Glucose-Stimulated Insulin Secretion and Insulin-Independent Peripheral Tissue Glucose Uptake Lead to Increased Heart and Skeletal Muscle Glucose Disposal , 2016, Diabetes.
[18] G. Taylor,et al. Amyloid cardiomyopathy associated with a novel apolipoprotein A–I Q172P variant , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[19] S. Hung,et al. Cellular Interaction and Cytotoxicity of the Iowa Mutation of Apolipoprotein A-I (ApoA-IIowa) Amyloid Mediated by Sulfate Moieties of Heparan Sulfate* , 2015, The Journal of Biological Chemistry.
[20] Bill C. A. Pulford,et al. CDApps: integrated software for experimental planning and data processing at beamline B23, Diamond Light Source , 2015, Journal of synchrotron radiation.
[21] G. Siligardi,et al. CD spectroscopy: an essential tool for quality control of protein folding. , 2015, Methods in molecular biology.
[22] R. Falk,et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity , 2014, EMBO molecular medicine.
[23] Shobini Jayaraman,et al. Amyloidogenic mutations in human apolipoprotein A‐I are not necessarily destabilizing – a common mechanism of apolipoprotein A‐I misfolding in familial amyloidosis and atherosclerosis , 2014, The FEBS journal.
[24] A. Schmidtchen,et al. The Epidermal Growth Factor Receptor Is a Regulator of Epidermal Complement Component Expression and Complement Activation , 2014, The Journal of Immunology.
[25] G. Hu,et al. Amyloidogenic variant of apolipoprotein A-I elicits cellular stress by attenuating the protective activity of angiogenin , 2014, Cell Death and Disease.
[26] M. Mörgelin,et al. The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils , 2012, Journal of Lipid Research.
[27] O. Gursky,et al. The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. , 2012, Biochemistry.
[28] T. Jávorfi,et al. Circular dichroism beamline B23 at the Diamond Light Source. , 2012, Journal of Synchrotron Radiation.
[29] D. Monti,et al. Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells , 2011, Journal of cellular and molecular medicine.
[30] P. Hawkins,et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. , 2011, The American journal of pathology.
[31] N. Grigorieff,et al. Nanoscale Flexibility Parameters of Alzheimer Amyloid Fibrils Determined by Electron Cryo-Microscopy** , 2010, Angewandte Chemie.
[32] J. Danesh,et al. Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.
[33] C. Röcken,et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. , 2009, The Journal of molecular diagnostics : JMD.
[34] P. Hawkins,et al. Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[35] R. Gallo,et al. Glycosaminoglycans and their proteoglycans: host‐associated molecular patterns for initiation and modulation of inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] Guido Franceschini,et al. Structure, function and amyloidogenic propensity of apolipoprotein A-I , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[37] E. Gruys,et al. Glycosaminoglycans are part of amyloid fibrils: Ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[38] J. Engler,et al. Förster resonance energy transfer measurements are consistent with a helical bundle model for lipid-free apolipoprotein A-I. , 2005, Biochemistry.
[39] E. Arbustini,et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. , 2004, Gastroenterology.
[40] A. Beaudet,et al. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. , 2004, Gene.
[41] J. Ávila,et al. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.
[42] A. Olofsson,et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. , 2002, Biochemical and biophysical research communications.
[43] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[44] M. Sousa,et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.
[45] M. Sunde,et al. Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure , 2001, Protein science : a publication of the Protein Society.
[46] D. Ostler,et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. , 2000, The American journal of pathology.
[47] J.. Neurodegenerative Diseases , 1996, GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia.
[48] L. Ailles,et al. Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. , 1992, Archives of pathology & laboratory medicine.
[49] S. Prusiner,et al. Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[50] R. Gregg,et al. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. , 1990, Genomics.
[51] S. Provencher,et al. Estimation of globular protein secondary structure from circular dichroism. , 1981, Biochemistry.
[52] B. Hazenberg. Amyloidosis , 1933, The Indian medical gazette.